First Experience with Omalizumab in a Child with Severe Persistent Asthma in Turkey: Case Report

Abstract

1764evere asthma continues to be a significant morbidity and mortality problem despite treatment according to international asthma guidelines.1 Humanized monoclonal anti-IgE antibody (omalizumab) is recently recommended at the fifth step of international asthma guidelines for the treatment of patients older than 12 years of age who have severe persistent allergic asthma uncontrolled despite treatment with high-dose inhaled corticosteroid (>800 µgr/day) in combination with a long-acting β2-agonist and oral leukotriene receptor antagonist and have serum total Ig E between 30-700 IU/ml. 2,3 In this article, we present our clinical experience with omalizumab in the first Turkish child case with severe persistent allergic asthma.First Experience with Omalizumab in a Child with Severe Persistent Asthma in Turkey: Case Report A AB BS S T TR RA AC CT T Hu ma n mo noc lo nal an ti-IgE an ti body (oma li zu mab) is re cently re com men ded at the fifth step of in ter na ti o nal ast hma gu i de li nes for the tre at ment of pa ti ents ol der than 12 ye ars of age who ha ve se ve re per sis tent al ler gic ast hma un con trol led des pi te tre at ment with high-do se in ha led cor ti cos te ro id (>800 µgr/day) in com bi na ti on with a long-ac ting β2-ago nist and oral le u kot ri e ne recep tor an ta go nist and ha ve se rum to tal Ig E bet we en 30-700 IU/ml. We star ted oma li zu mab as addon tre at ment to a se ve re per sis tent ast hma tic ca se who had two se ve re ast hma at tacks in the last thre e-month pe ri od, one of which was comp li ca ted with pne u mo me di as ti ni um. This is the first expe ri en ce with oma li zu mab in a child with se ve re ast hma re por ted from our co untry. The first se venmonth of oma li zu mab tre at ment re sul ted in sig ni fi cant im pro ve ments in qu a lity of li fe and pul mo nary func ti ons as well as re duc ti ons in in ha led cor ti cos te ro id do se and da ily symptom sco res.K Ke ey y W Wo or rd ds s: : Ast hma; child; oma li zu mab Ö ÖZ ZE ET T Son yıl lar da, bir in san mo nok lo nal an ti IgE an ti ko ru olan oma li zu mab, ulus la ra ra sı te da vi kı -la vuz la rın da be şin ci ba sa mak ta yük sek doz in ha ler kor ti kos te ro id (>800 µgr/gün), in ha ler uzun etki li β2 ago nist ve oral lö kot ri en re sep tör an ta go nist te da vi si ne rağ men as tı mı kon trol al tı na alı na ma yan ve se rum to tal IgE dü ze yi 30-700 IU/ml ara sın da olan, 12 ya şın dan bü yük, ağır per sistan al ler jik as tım lı has ta lar için öne ril mek te dir. Kli ni ği miz de, ağır per sis tan as tım ta nı sıy la iz le nen ve son üç ay lık dö nem de bi ri pno mo me di as ti num ile komp li ke iki ağır as tım ata ğı ge li şen ol gu muza oma li zu mab te da vi si baş lan dı. Ol gu muz, ül ke miz de ço cuk luk ça ğı as tım po pü las yo nun da bil diri len ilk oma li zu mab uy gu la ma sı olup, te da vi nin ilk yedi ay lık dö ne mi de ğer len di ril di ğin de te da vi ön ce si ne gö re gün lük as tım semp tom sko run da azal ma, ha yat ya şam ka li te sin de ve so lu num fonksi yon ...